Kimia Biosciences Limited reported a 22.7% decline in net profit to ₹743.37 lakh for the financial year ended March 31, 2026, down from ₹961.24 lakh in the prior year. Revenue from operations decreased to ₹11,488.38 lakh compared to ₹11,892.08 lakh in FY25. The board approved the audited standalone financial results at its meeting held on May 29, 2026. The company submitted newspaper cuttings of the results, published in the Financial Express and Jansatta on May 31, 2026, to the BSE under Regulation 47 of the SEBI (LODR) Regulations, 2015.

For the quarter ended March 31, 2026, the company recorded a profit of ₹37.31 lakh, a significant drop from the ₹199.17 lakh reported in the corresponding quarter of the previous year. Revenue for the quarter stood at ₹2,719.98 lakh. Total expenses for the year increased to ₹10,804.54 lakh from ₹10,660.69 lakh in the previous year.

The statutory auditor, Neeraj Arora & Associates, issued an unmodified opinion on the financial statements. The auditor identified revenue recognition and research and development (R&D) expenditure as key audit matters. The report noted that the company reassessed its accounting treatment for certain R&D expenditures during the reporting period to comply with Ind AS 38, capitalizing costs that met the recognition criteria for intangible assets.

Financial Performance

The company’s earnings per share (EPS) for the year stood at ₹1.64, down from ₹2.04 in the previous year. Finance costs for the year reduced to ₹351.57 lakh from ₹455.70 lakh. The company did not declare any dividend for the year ended March 31, 2026.

Balance Sheet Highlights

The company’s total assets stood at ₹10,319.73 lakh as of March 31, 2026, down from ₹11,121.16 lakh a year earlier. Intangible assets increased significantly to ₹709.92 lakh from ₹237.82 lakh, primarily due to the capitalization of R&D costs. Borrowings, including non-current and current liabilities, totaled ₹3,462.79 lakh.

Regulatory Disclosures

The auditor confirmed that the company has maintained adequate internal financial controls over financial reporting. The report also noted that the company redeemed preference share capital amounting to ₹8 crore during the first and second quarters of the financial year in accordance with the terms of issue. The company used SAP Basics accounting software, which features an audit trail facility operated throughout the year.

Kimia Biosciences Limited has announced that its board meeting is scheduled to be held on Friday, May 29, 2026. The meeting has been convened in accordance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Agenda for the Meeting

The primary agenda for the board meeting is to consider and approve the audited financial results for the quarter and financial year ended March 31, 2026. The approval will include the standalone financial results along with the accompanying audit report.

Trading Window Closure

In continuation of an earlier intimation dated March 25, 2026, the company has informed that the trading window remains closed. This closure, effective from April 1, 2026, is in line with the company's Code of Conduct to regulate, monitor, and report trading by insiders for the prevention of insider trading. The window will continue to remain closed until 48 hours after the declaration of the aforementioned financial results.

Key Details

The information regarding the financial results will be made available on the company's official website.